KR20230112605A - 키나아제 억제제 및 그의 용도 - Google Patents

키나아제 억제제 및 그의 용도 Download PDF

Info

Publication number
KR20230112605A
KR20230112605A KR1020237007882A KR20237007882A KR20230112605A KR 20230112605 A KR20230112605 A KR 20230112605A KR 1020237007882 A KR1020237007882 A KR 1020237007882A KR 20237007882 A KR20237007882 A KR 20237007882A KR 20230112605 A KR20230112605 A KR 20230112605A
Authority
KR
South Korea
Prior art keywords
optionally substituted
alkyl
pharmaceutically acceptable
compound
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237007882A
Other languages
English (en)
Korean (ko)
Inventor
첸 첸
Original Assignee
에이비엠 쎄라퓨틱스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이비엠 쎄라퓨틱스 코포레이션 filed Critical 에이비엠 쎄라퓨틱스 코포레이션
Publication of KR20230112605A publication Critical patent/KR20230112605A/ko
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237007882A 2020-08-07 2021-08-06 키나아제 억제제 및 그의 용도 Pending KR20230112605A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063063113P 2020-08-07 2020-08-07
US63/063,113 2020-08-07
PCT/US2021/044907 WO2022032071A1 (en) 2020-08-07 2021-08-06 Kinase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
KR20230112605A true KR20230112605A (ko) 2023-07-27

Family

ID=77711412

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237007882A Pending KR20230112605A (ko) 2020-08-07 2021-08-06 키나아제 억제제 및 그의 용도

Country Status (10)

Country Link
US (1) US20230303570A1 (https=)
EP (1) EP4192582A1 (https=)
JP (1) JP2023538521A (https=)
KR (1) KR20230112605A (https=)
CN (1) CN116710453A (https=)
AU (1) AU2021321536A1 (https=)
BR (1) BR112023002248A2 (https=)
CA (1) CA3179671A1 (https=)
MX (1) MX2023001312A (https=)
WO (1) WO2022032071A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4577546A1 (en) * 2022-08-25 2025-07-02 Enliven Inc. Naphthyridine compounds for inhibition of raf kinases
WO2024199388A1 (zh) * 2023-03-29 2024-10-03 微境生物医药科技(上海)有限公司 作为myt1抑制剂的化合物
WO2025064567A1 (en) * 2023-09-19 2025-03-27 Enliven Inc. Tricyclic phenols for inhibition of raf kinases
WO2025152919A1 (en) * 2024-01-15 2025-07-24 Impact Therapeutics (Shanghai) , Inc. Crystal forms of a weel inhibitor and preparation method thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006503802A (ja) * 2002-04-03 2006-02-02 エフ.ホフマン−ラ ロシュ アーゲー イミダゾ縮合化合物
EP2348020A1 (en) 2009-12-23 2011-07-27 Esteve Química, S.A. Preparation process of erlotinib
FR2974088A1 (fr) * 2011-04-12 2012-10-19 Pf Medicament Composes pyrazolo[3,4-b]pyridines tri- et tetracycliques comme agent anticancereux
RU2019102647A (ru) * 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
EP3684772B1 (en) * 2017-09-20 2023-12-06 ABM Therapeutics Corporation Cyclic iminopyrimidine derivatives as kinase inhibitors
CN110950867A (zh) * 2018-09-27 2020-04-03 首药控股(北京)有限公司 一种fgfr4激酶抑制剂及其制备方法和用途

Also Published As

Publication number Publication date
CA3179671A1 (en) 2022-02-10
EP4192582A1 (en) 2023-06-14
JP2023538521A (ja) 2023-09-08
CN116710453A (zh) 2023-09-05
WO2022032071A1 (en) 2022-02-10
MX2023001312A (es) 2023-04-12
AU2021321536A1 (en) 2023-03-09
US20230303570A1 (en) 2023-09-28
BR112023002248A2 (pt) 2023-03-07

Similar Documents

Publication Publication Date Title
AU2022349569A1 (en) Pyridine derivative and use thereof
KR102609431B1 (ko) Phd 저해제로서의 활성을 갖는 융합된 바이시클릭 헤테로아릴 유도체
EP3466929B1 (en) Heterocyclic compounds useful as pdk1 inhibitors
EP3152210B1 (en) Tank-binding kinase inhibitor compounds
JP6923543B2 (ja) Nr2b選択的nmda調節因子としての置換1,2,3−トリアゾール
TWI588141B (zh) 經取代之苄基吲唑
ES2708211T3 (es) 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas
AU2019323035B2 (en) Pyrazine compounds and uses thereof
KR20230112605A (ko) 키나아제 억제제 및 그의 용도
JP2020525522A (ja) Rho−関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
TWI785474B (zh) 用作選擇性Aurora A抑制劑的新型雜環化合物
EP3952870A1 (en) Phosphatidylinositol 3-kinase inhibitors
CN112457326B (zh) 一类芳香杂环并内酰胺类化合物、制备方法和用途
HK40100224A (zh) 激酶抑制剂及其用途
CN103443107A (zh) 噻唑并嘧啶化合物
WO2025072395A1 (en) Triazolopyridinyl compounds as kinase inhibitors
AU2024353744A1 (en) Triazolopyridinyl compounds as kinase inhibitors
JP2025539086A (ja) 造血前駆細胞キナーゼ1のピリドン及びピリミジノン阻害剤
HK1249512B (en) Fused bicyclic heteroaryl derivatives having activity as phd inhibitors
HK1231042B (en) Flap modulators
HK1236197A1 (en) Tank-binding kinase inhibitor compounds
HK1236197B (en) Tank-binding kinase inhibitor compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230306

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240806

Comment text: Request for Examination of Application